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Abstract Endocrine therapy for breast cancer may affect
cognition. The purpose of this study was to examine
whether cognitive function improves after cessation of
adjuvant endocrine therapy. Change in cognitive function
was assessed in 100 postmenopausal breast cancer patients
in the BIG 1-98 trial, who were randomized to receive
5 years of adjuvant tamoxifen or letrozole alone or in
sequence. Cognitive function was evaluated by computer-
ized tests during the fifth year of trial treatment (Y5) and
1 year after treatment completion (Y6). Cognitive test
scores were standardized according to age-specific norms
and the change assessed using the Wilcoxon signed-rank
test. There was significant improvement in the composite
cognitive function score from Y5 to Y6 (median of
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change = 0.22, effect size = 0.53, P \ 0.0001). This
improvement was consistent in women taking either
tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002,
respectively). For postmenopausal patients who received
either adjuvant letrozole or tamoxifen alone or in sequence,
cognitive function improved after cessation of treatment.
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Introduction
Most postmenopausal early stage breast cancer patients
have hormone receptor-positive disease and are, therefore,
treated with endocrine therapy [1]. Several studies suggest
that adjuvant endocrine therapy is associated with impaired
cognitive function during treatment [2–5], and that
tamoxifen may have a more adverse effect than aromatase
inhibitors [2, 6, 7]. No published study has specifically
evaluated the trajectory of cognitive function after ceasing
adjuvant endocrine therapy. We evaluated the change in
cognitive function 1 year after cessation of adjuvant
endocrine therapy in a subgroup of postmenopausal early-
stage breast cancer patients treated in the BIG 1-98 trial.
Methods
The BIG 1-98 trial (March 1998–May 2003) randomized
8010 postmenopausal women with hormone receptor-
positive tumors to receive one of four adjuvant endocrine
therapy options after stratification by institution and che-
motherapy (Fig. 1) [8, 9]. A substudy assessed cognitive
function at Y5 (during the fifth year on endocrine therapy)
and Y6 (approximately 1 year after cessation of therapy).
Cross-sectional Y5 data, showing that patients on letrozole
had better overall cognitive function than those on
tamoxifen, have been previously reported [6]. We now
report longitudinal data assessing cognitive changes
between Y5 and Y6. The substudy protocol was approved
by the local and International Breast Cancer Study Group
(IBCSG) ethics committees and the required health
authorities of each participating center. All the patients
gave informed consent to participate in the substudy and
parent study.
Objective cognitive function was assessed using a brief
computerized test battery (CogState Ltd; http://www.
cogstate.com) which is free from practice effects [10–13].
Details of the test battery are given in Table 1. A com-
posite score, representing the average standardized score of
each task for each individual, was prospectively defined as
the primary endpoint.
Scores for each task were transformed, then standard-
ized according to age-specific norms (Z-scores) [14]. A
positive Z-score indicates a patient performed better than
average for her age group. The composite score was cal-
culated by the mean of the Z-scores for all tasks. For five
patients who were missing data on some individual tasks,
the mean of the scores of the completed tasks was taken
as their composite score. A positive difference in the
composite score from Y5 to Y6 indicates that cognitive
function improved.
Change in cognitive function from Y5 to Y6 was
assessed using the Wilcoxon signed-rank test, first for all
the patients and then separately for each treatment group.
No substantial normality violations were noted. The effect
of endocrine treatment on change in cognitive function was
assessed using two-way ANOVA controlling for the effect
of language. Descriptive statistics of change in perfor-
mance (mean, SD, and effect size) were calculated per
treatment group for each task. Effect size is defined as the
difference between Y6 and Y5 measurements divided by
the standard deviation of the difference.
The effect of treatment on the changes in cognitive
function was also assessed nonparametrically using the
stratified Wilcoxon Rank Sum test (adjusted for language).
To account for potential imbalances between treatment
groups, a linear model was created for the CogState com-
posite score to further evaluate the treatment effect using a
stepwise selection procedure with the following covariates:
treatment, language, age, chemotherapy received, tumor
size, history of depression, treatment for depression at Y5,
time between assessments, and ECOG performance status
at Y5. Treatment and language were forced into the model.
Comparisons of scores between the two monotherapy arms,
and between monotherapy and sequential therapy arms for
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tamoxifen and for letrozole, respectively, were based on
two-way ANOVA controlling for language. All P values
were based on two-sided tests. A P value \0.05 indicates
statistical significance.
Of the 135 patients recruited to this substudy, 35 were
ineligible for this analysis (Fig. 1), leaving 100 patients as
eligible for inclusion. The Y6 assessment was undertaken a
median of 365.5 days (range 191–699 days) after ceasing
protocol endocrine therapy.
Results
There was significant improvement in cognition, as mea-
sured by the change in composite score, from Y5 to Y6
(median of change = 0.22, effect size = 0.53, P \0.0001)
(Fig. 2, Table 2). This finding was consistent in women
taking either tamoxifen or letrozole at Y5 (median of
change = 0.20, effect size = 0.54, and P = 0.0006; or
median of change = 0.23, effect size = 0.53, and
P = 0.0002, respectively) and across all cognitive tasks
(though not statistically significant for the learning task)
(Table 2). The effect size, defined as the difference in score
between Y5 and Y6 divided by the standard deviation of
the difference, was small for the individual tasks
(range 0.17–0.35) and moderate for the change in overall
cognition as measured by the composite score (0.53). After
adjusting for language and any significant covariates, the
change in cognitive function (Y6–Y5) of patients taking
letrozole at Y5 was not different from those taking
tamoxifen at Y5. Exploratory analyses revealed no
Table 1 Cogstate cognitive
function test battery
a Subjects were required to
learn a 12-item shopping list
and recall it after 20 min
Task Verbal/
non-verbal
Cognitive domain Outcome measured
Detection Non-
verbal
Speed of psychomotor function Performance speed
Identification and monitoring Non-
verbal
Visual attention Performance speed
Learning Non-
verbal
Visual learning and memory Performance accuracy
Memory Non-
verbal
Attention and working memory Performance accuracy
Shopping lista Verbal Verbal learning and memory Number of correct responses
Shopping list delayed recalla Verbal Verbal learning and memory Number of correct responses
135 patients enrolled
L T
Y5 assessment >2 days
after cessation ET (9)
L   T T   L
Received L after comple-
tion of protocol ET (13)
32
L
14
T
29
L   T
25
T   L
100 patients with Y5 and Y6 
assessments
Crossover T to L (1)
Missing/incomplete 
data (12) 
1
40 24 38 33
3 0 3 3
2 7 2 2
3 2 4 3
a/na/n n/a
Exclusions (35 total)
Fig. 1 CONSORT diagram of
the BIG 1-98 Cognitive
Function Substudy. T tamoxifen
for 5 years, L letrozole for
5 years, T ? L tamoxifen for 2
years followed by letrozole for
three years, L ? T letrozole for
2 years followed by tamoxifen
for 3 years, ET endocrine
therapy, Y5 cognitive function
assessment taken at the end of
5 years of ET, Y6 cognitive
function assessment taken
approximately 1 year after
completion of ET
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differences in the change in cognitive function (Y6–Y5)
between the monotherapy arms or the monotherapy versus
sequential arms.
Discussion
In this substudy, cognitive function was better approxi-
mately 1 year after cessation of adjuvant endocrine therapy
as compared with the fifth year on therapy. For the com-
posite score, this improvement (effect size = 0.53) was, by
convention, moderate in magnitude. Changes in cognitive
function of a similar magnitude have been observed in
healthy adults given methylphenidate for cognitive
enhancement [15, 16]. In addition, stressing the clinical
relevance of our findings, the effect size observed is larger
than that required by the FDA for approval of drugs that
enhance cognition in diseases such as schizophrenia [17].
Although there was no untreated control group in the
randomized BIG 1-98 trial, the improvement is not thought
to be because of practice effects as these do not operate in
the CogState test battery, and the magnitude of improve-
ment is too large. Cognitive function was not assessed
before starting endocrine therapy, and so we cannot cal-
culate how cognition 1 year after cessation of therapy
compares with baseline cognitive function before com-
mencing adjuvant endocrine therapy. Nevertheless, this
study suggests that if adjuvant endocrine therapy affects
cognition in postmenopausal women, that effect is at least
partly reversible with cessation of therapy, which is a
-0.3
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Fig. 2 Change in median age-adjusted composite score from the
assessment taken at the end of endocrine therapy (Y5) to the
assessment taken approximately 1 year after completion of endocrine
therapy (Y6) according to endocrine therapy received, showing
significant improvement in cognition, as measured by the composite
score, from Y5 to Y6
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relevant and new finding for postmenopausal women with
hormone receptor positive breast cancer.
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